Assertio Holdings, Inc. (ASRT)
USD 0.62
(0.29%)
USD 0.62
(0.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 125.04 Million USD | -29.58% |
| 2022 | 137.48 Million USD | 44.45% |
| 2021 | 95.18 Million USD | 10.16% |
| 2020 | 86.4 Million USD | -60.73% |
| 2019 | 219.99 Million USD | -24.99% |
| 2018 | 293.29 Million USD | -4.81% |
| 2017 | 308.12 Million USD | -16.38% |
| 2016 | 368.48 Million USD | 34.07% |
| 2015 | 274.83 Million USD | -26.75% |
| 2014 | 375.21 Million USD | 195.18% |
| 2013 | 127.11 Million USD | 49.94% |
| 2012 | 84.77 Million USD | -33.47% |
| 2011 | 127.42 Million USD | 75.36% |
| 2010 | 72.66 Million USD | 38.49% |
| 2009 | 52.47 Million USD | 80.5% |
| 2008 | 29.07 Million USD | -53.85% |
| 2007 | 62.98 Million USD | 692.22% |
| 2006 | 7.95 Million USD | 127.36% |
| 2005 | 3.49 Million USD | 1626.23% |
| 2004 | 202.56 Thousand USD | -79.37% |
| 2003 | 981.99 Thousand USD | -40.89% |
| 2002 | 1.66 Million USD | -54.78% |
| 2001 | 3.67 Million USD | 57.12% |
| 2000 | 2.33 Million USD | 208.11% |
| 1999 | 758.81 Thousand USD | -41.63% |
| 1998 | 1.3 Million USD | 62.5% |
| 1997 | 800 Thousand USD | 166.67% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 15.54 Million USD | -15.35% |
| 2024 Q2 | 15.52 Million USD | 43.1% |
| 2023 FY | 96.82 Million USD | -29.58% |
| 2023 Q2 | 36.21 Million USD | -2.11% |
| 2023 Q3 | 28.56 Million USD | -21.13% |
| 2023 Q4 | 18.35 Million USD | -35.74% |
| 2023 Q1 | 36.99 Million USD | -16.55% |
| 2022 FY | 137.48 Million USD | 44.45% |
| 2022 Q4 | 44.33 Million USD | 46.8% |
| 2022 Q1 | 32.34 Million USD | 13.75% |
| 2022 Q2 | 30.6 Million USD | -5.38% |
| 2022 Q3 | 30.2 Million USD | -1.31% |
| 2021 Q2 | 21.45 Million USD | -6.21% |
| 2021 Q3 | 22.42 Million USD | 4.52% |
| 2021 Q4 | 28.43 Million USD | 26.81% |
| 2021 FY | 95.18 Million USD | 10.16% |
| 2021 Q1 | 22.87 Million USD | -2.26% |
| 2020 Q2 | 15.37 Million USD | -21.21% |
| 2020 Q3 | 28.1 Million USD | 82.74% |
| 2020 FY | 86.4 Million USD | -60.73% |
| 2020 Q1 | 19.51 Million USD | -65.55% |
| 2020 Q4 | 23.4 Million USD | -16.72% |
| 2019 Q4 | 56.66 Million USD | 7.11% |
| 2019 Q2 | 55.07 Million USD | -0.5% |
| 2019 Q3 | 52.9 Million USD | -3.95% |
| 2019 FY | 219.99 Million USD | -24.99% |
| 2019 Q1 | 55.35 Million USD | 32.13% |
| 2018 Q3 | 74.51 Million USD | 23.13% |
| 2018 FY | 293.29 Million USD | -4.81% |
| 2018 Q1 | 116.36 Million USD | 51.7% |
| 2018 Q2 | 60.52 Million USD | -47.99% |
| 2018 Q4 | 41.89 Million USD | -43.78% |
| 2017 Q4 | 76.7 Million USD | -1.68% |
| 2017 FY | 308.12 Million USD | -16.38% |
| 2017 Q1 | 72.67 Million USD | -28.23% |
| 2017 Q2 | 80.73 Million USD | 11.09% |
| 2017 Q3 | 78.01 Million USD | -3.36% |
| 2016 FY | 368.48 Million USD | 34.07% |
| 2016 Q4 | 101.25 Million USD | 12.15% |
| 2016 Q3 | 90.28 Million USD | -5.68% |
| 2016 Q2 | 95.71 Million USD | 17.83% |
| 2016 Q1 | 81.23 Million USD | -9.91% |
| 2015 Q2 | 71.63 Million USD | 146.26% |
| 2015 Q1 | 29.09 Million USD | -84.8% |
| 2015 Q3 | 83.94 Million USD | 17.17% |
| 2015 Q4 | 90.16 Million USD | 7.41% |
| 2015 FY | 274.83 Million USD | -26.75% |
| 2014 FY | 375.21 Million USD | 195.18% |
| 2014 Q4 | 191.35 Million USD | 298.97% |
| 2014 Q3 | 47.96 Million USD | -23.94% |
| 2014 Q2 | 63.05 Million USD | -13.43% |
| 2014 Q1 | 72.84 Million USD | 89.49% |
| 2013 FY | 127.11 Million USD | 49.94% |
| 2013 Q1 | 24.69 Million USD | 1.71% |
| 2013 Q3 | 35.7 Million USD | 26.29% |
| 2013 Q2 | 28.27 Million USD | 14.52% |
| 2013 Q4 | 38.44 Million USD | 7.65% |
| 2012 Q3 | 31.51 Million USD | 148.81% |
| 2012 Q1 | 16.31 Million USD | 41.73% |
| 2012 FY | 84.77 Million USD | -33.47% |
| 2012 Q4 | 24.27 Million USD | -22.99% |
| 2012 Q2 | 12.66 Million USD | -22.36% |
| 2011 Q1 | 81.46 Million USD | 313.05% |
| 2011 Q2 | 19.07 Million USD | -76.58% |
| 2011 Q4 | 11.51 Million USD | -25.1% |
| 2011 FY | 127.42 Million USD | 75.36% |
| 2011 Q3 | 15.37 Million USD | -19.43% |
| 2010 Q3 | 17.62 Million USD | -17.77% |
| 2010 Q1 | 13.87 Million USD | 19.6% |
| 2010 Q2 | 21.43 Million USD | 54.46% |
| 2010 Q4 | 19.72 Million USD | 11.88% |
| 2010 FY | 72.66 Million USD | 38.49% |
| 2009 FY | 52.47 Million USD | 80.5% |
| 2009 Q1 | 8.84 Million USD | 17.71% |
| 2009 Q2 | 10.37 Million USD | 17.41% |
| 2009 Q3 | 21.64 Million USD | 108.57% |
| 2009 Q4 | 11.6 Million USD | -46.39% |
| 2008 Q4 | 7.51 Million USD | -35.89% |
| 2008 Q3 | 11.71 Million USD | 118.85% |
| 2008 Q2 | 5.35 Million USD | 19.17% |
| 2008 Q1 | 4.49 Million USD | 4.81% |
| 2008 FY | 29.07 Million USD | -53.85% |
| 2007 Q4 | 4.28 Million USD | -91.78% |
| 2007 Q1 | 3.52 Million USD | -27.83% |
| 2007 FY | 62.98 Million USD | 692.22% |
| 2007 Q2 | 3.03 Million USD | -13.74% |
| 2007 Q3 | 52.13 Million USD | 1615.56% |
| 2006 FY | 7.95 Million USD | 127.36% |
| 2006 Q3 | 638.36 Thousand USD | -45.09% |
| 2006 Q2 | 1.16 Million USD | -8.3% |
| 2006 Q1 | 1.26 Million USD | -43.77% |
| 2006 Q4 | 4.88 Million USD | 664.73% |
| 2005 FY | 3.49 Million USD | 1626.23% |
| 2005 Q1 | 18.75 Thousand USD | 0.0% |
| 2005 Q2 | 428.46 Thousand USD | 2185.16% |
| 2005 Q3 | 795.03 Thousand USD | 85.55% |
| 2005 Q4 | 2.25 Million USD | 183.58% |
| 2004 Q4 | 18.75 Thousand USD | -70.75% |
| 2004 Q1 | 119.72 Thousand USD | 7.08% |
| 2004 FY | 202.56 Thousand USD | -79.37% |
| 2004 Q2 | - USD | -100.0% |
| 2004 Q3 | 64.09 Thousand USD | 0.0% |
| 2003 Q3 | 364.55 Thousand USD | 207.27% |
| 2003 Q4 | 111.81 Thousand USD | -69.33% |
| 2003 Q2 | 118.64 Thousand USD | -69.34% |
| 2003 Q1 | 386.98 Thousand USD | 33.92% |
| 2003 FY | 981.99 Thousand USD | -40.89% |
| 2002 Q4 | 288.97 Thousand USD | 106.52% |
| 2002 FY | 1.66 Million USD | -54.78% |
| 2002 Q3 | 139.92 Thousand USD | -77.08% |
| 2002 Q2 | 610.56 Thousand USD | -1.79% |
| 2002 Q1 | 621.71 Thousand USD | -37.15% |
| 2001 Q3 | 1.2 Million USD | -85.49% |
| 2001 Q1 | 755.74 Thousand USD | 43.91% |
| 2001 FY | 3.67 Million USD | 57.12% |
| 2001 Q2 | 8.32 Million USD | 1001.96% |
| 2001 Q4 | 989.28 Thousand USD | -18.15% |
| 2000 FY | 2.33 Million USD | 208.11% |
| 2000 Q4 | 525.14 Thousand USD | -0.96% |
| 2000 Q3 | 530.22 Thousand USD | -26.99% |
| 2000 Q1 | 556.4 Thousand USD | 250.34% |
| 2000 Q2 | 726.21 Thousand USD | 30.52% |
| 1999 FY | 758.81 Thousand USD | -41.63% |
| 1999 Q4 | 158.81 Thousand USD | -47.06% |
| 1999 Q2 | 200 Thousand USD | -33.33% |
| 1999 Q1 | 300 Thousand USD | -50.0% |
| 1999 Q3 | 300 Thousand USD | 50.0% |
| 1998 FY | 1.3 Million USD | 62.5% |
| 1998 Q2 | 200 Thousand USD | 0.0% |
| 1998 Q3 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 600 Thousand USD | 200.0% |
| 1998 Q1 | 200 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | -50.0% |
| 1997 Q2 | 200 Thousand USD | 0.0% |
| 1997 Q4 | 200 Thousand USD | 100.0% |
| 1997 FY | 800 Thousand USD | 166.67% |
| 1997 Q1 | 200 Thousand USD | 0.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 61.661% |
| Embecta Corp. | 749.9 Million USD | 83.325% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 59.041% |
| Dynavax Technologies Corporation | 182.11 Million USD | 31.336% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -71.143% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 74.496% |
| PainReform Ltd. | -15 Thousand USD | 833760.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -320.305% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1399.538% |
| SCYNEXIS, Inc. | 124.51 Million USD | -0.427% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -22473.203% |
| Cosmos Health Inc. | 4.34 Million USD | -2774.975% |
| Journey Medical Corporation | 52.52 Million USD | -138.093% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1399.538% |
| Safety Shot Inc | -74.45 Thousand USD | 168047.943% |
| Alpha Teknova, Inc. | 10.29 Million USD | -1114.54% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 70.961% |
| Bright Green Corporation | -237.01 Thousand USD | 52859.729% |
| Procaps Group, S.A. | 239.56 Million USD | 47.803% |
| Theratechnologies Inc. | 62.12 Million USD | -101.273% |
| Harrow Health, Inc. | 90.55 Million USD | -38.095% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -2535.385% |
| Biofrontera Inc. | 16.62 Million USD | -652.084% |
| DURECT Corporation | 6.83 Million USD | -1730.61% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 76.124% |
| Cronos Group Inc. | 6.99 Million USD | -1688.741% |
| OptiNose, Inc. | 62.35 Million USD | -100.547% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 71.655% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 41370.297% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -3994.365% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 59.634% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -2218.076% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -273.438% |
| Radius Health, Inc. | 307.71 Million USD | 59.362% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -1140.826% |
| ProPhase Labs, Inc. | 16.23 Million USD | -670.054% |
| Phibro Animal Health Corporation | 312.48 Million USD | 59.983% |
| Procaps Group S.A. | 239.56 Million USD | 47.803% |
| Alvotech | -69.42 Million USD | 280.129% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -9504.378% |
| Viatris Inc. | 6.43 Billion USD | 98.058% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1336.684% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -129.086% |
| SIGA Technologies, Inc. | 122.09 Million USD | -2.422% |
| Tilray Brands, Inc. | 223.35 Million USD | 44.012% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -198.803% |
| Shineco, Inc. | 882.16 Thousand USD | -14075.191% |
| PetIQ, Inc. | 252.74 Million USD | 50.523% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 16871.863% |
| Incannex Healthcare Limited | 12 Thousand USD | -1041975.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 93.231% |
| Alimera Sciences, Inc. | 61.17 Million USD | -104.429% |
| Silver Spike Investment Corp. | 8.1 Million USD | -1443.32% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1836085.905% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -2883.631% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -1807.398% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5288.376% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -361.146% |
| Hempacco Co., Inc. | -1.21 Million USD | 10385.047% |
| Talphera, Inc. | -4.89 Million USD | 2654.627% |
| Alvotech | -69.42 Million USD | 280.129% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 43.589% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 82.376% |
| Currenc Group, Inc. | 17.35 Million USD | -620.482% |
| Kamada Ltd. | 52.59 Million USD | -137.769% |
| Indivior PLC | 907 Million USD | 86.213% |
| Evoke Pharma, Inc. | 4.97 Million USD | -2411.654% |
| Flora Growth Corp. | 17.73 Million USD | -604.978% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 5288.376% |
| Evolus, Inc. | 140.52 Million USD | 11.014% |
| HUTCHMED (China) Limited | 453.55 Million USD | 72.429% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 63.645% |
| Akanda Corp. | 111.44 Thousand USD | -112102.891% |